707 related articles for article (PubMed ID: 12408664)
1. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.
Johnson BW; Chambers TV; Crabtree MB; Bhatt TR; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2002 Sep; 67(3):260-5. PubMed ID: 12408664
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction.
Johnson BW; Chambers TV; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2004 Jan; 70(1):89-97. PubMed ID: 14971704
[TBL] [Abstract][Full Text] [Related]
3. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes.
Bhatt TR; Crabtree MB; Guirakhoo F; Monath TP; Miller BR
Am J Trop Med Hyg; 2000 Apr; 62(4):480-4. PubMed ID: 11220763
[TBL] [Abstract][Full Text] [Related]
4. Growth characteristics of the veterinary vaccine candidate ChimeriVax-West Nile (WN) virus in Aedes and Culex mosquitoes.
Johnson BW; Chambers TV; Crabtree MB; Arroyo J; Monath TP; Miller BR
Med Vet Entomol; 2003 Sep; 17(3):235-43. PubMed ID: 12941006
[TBL] [Abstract][Full Text] [Related]
5. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand.
Higgs S; Vanlandingham DL; Klingler KA; McElroy KL; McGee CE; Harrington L; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2006 Nov; 75(5):986-93. PubMed ID: 17124001
[TBL] [Abstract][Full Text] [Related]
6. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
7. Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells.
Brandler S; Brown N; Ermak TH; Mitchell F; Parsons M; Zhang Z; Lang J; Monath TP; Guirakhoo F
Am J Trop Med Hyg; 2005 Jan; 72(1):74-81. PubMed ID: 15728870
[TBL] [Abstract][Full Text] [Related]
8. Vector competence of Aedes albopictus and Aedes aegypti (Diptera: Culicidae) for DEN2-43 and New Guinea C virus strains of dengue 2 virus.
Guo XX; Zhu XJ; Li CX; Dong YD; Zhang YM; Xing D; Xue RD; Qin CF; Zhao TY
Acta Trop; 2013 Dec; 128(3):566-70. PubMed ID: 23962388
[TBL] [Abstract][Full Text] [Related]
9. Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.
Sardelis MR; Edelman R; Klein TA; Innis BL; Putnak JR; Jones JW; Turell MJ
Am J Trop Med Hyg; 2000 Jun; 62(6):698-701. PubMed ID: 11304057
[TBL] [Abstract][Full Text] [Related]
10. Vector competence of Aedes albopictus and Aedes aegypti (Diptera: Culicidae) for the DEN2-FJ10 and DEN2-FJ11 strains of the dengue 2 virus in Fujian, China.
Guo XX; Li CX; Zhang YM; Xing D; Dong YD; Zhang HD; Qin CF; Zhao TY
Acta Trop; 2016 Sep; 161():86-90. PubMed ID: 27260668
[TBL] [Abstract][Full Text] [Related]
11. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
12. The impact of temperature and Wolbachia infection on vector competence of potential dengue vectors Aedes aegypti and Aedes albopictus in the transmission of dengue virus serotype 1 in southern Taiwan.
Tsai CH; Chen TH; Lin C; Shu PY; Su CL; Teng HJ
Parasit Vectors; 2017 Nov; 10(1):551. PubMed ID: 29116011
[TBL] [Abstract][Full Text] [Related]
13. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes.
Troyer JM; Hanley KA; Whitehead SS; Strickman D; Karron RA; Durbin AP; Murphy BR
Am J Trop Med Hyg; 2001 Nov; 65(5):414-9. PubMed ID: 11716092
[TBL] [Abstract][Full Text] [Related]
14. Dengue 3 virus infection of Aedes albopictus and Aedes aegypti: comparison of parent and progeny candidate vaccine viruses.
Schoepp RJ; Beaty BJ; Eckels KH
Am J Trop Med Hyg; 1990 Jan; 42(1):89-96. PubMed ID: 2301711
[TBL] [Abstract][Full Text] [Related]
15. Substitution of wild-type yellow fever Asibi sequences for 17D vaccine sequences in ChimeriVax-dengue 4 does not enhance infection of Aedes aegypti mosquitoes.
McGee CE; Tsetsarkin K; Vanlandingham DL; McElroy KL; Lang J; Guy B; Decelle T; Higgs S
J Infect Dis; 2008 Mar; 197(5):686-92. PubMed ID: 18266608
[TBL] [Abstract][Full Text] [Related]
16. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
[TBL] [Abstract][Full Text] [Related]
17. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE).
Reid M; Mackenzie D; Baron A; Lehmann N; Lowry K; Aaskov J; Guirakhoo F; Monath TP
Am J Trop Med Hyg; 2006 Oct; 75(4):659-63. PubMed ID: 17038690
[TBL] [Abstract][Full Text] [Related]
18. The occurrence, diversity and blood feeding patterns of potential vectors of dengue and yellow fever in Kacheliba, West Pokot County, Kenya.
Chepkorir E; Venter M; Lutomiah J; Mulwa F; Arum S; Tchouassi DP; Sang R
Acta Trop; 2018 Oct; 186():50-57. PubMed ID: 30006028
[TBL] [Abstract][Full Text] [Related]
19. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation.
Schoepp RJ; Beaty BJ; Eckels KH
Am J Trop Med Hyg; 1991 Aug; 45(2):202-10. PubMed ID: 1877715
[TBL] [Abstract][Full Text] [Related]
20. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
